NEW YORK (GenomeWeb News) – PDI and Transgenomic today announced a collaboration to commercialize Transgenomic's molecular diagnostic test that identifies specific genes that influence the safety and effectiveness of commonly used cardiovascular drugs.
NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market on Tuesday that its second quarter sales dropped 20 percent year over year.
Industry reactions to the US Supreme Court's decision to invalidate patents on isolated gene sequences were immediate and ranged from elation to disappointment.
Transgenomic announced this week that it has signed an agreement with Amgen to develop an IVD test to identify NRAS and KRAS mutated patients with advanced colorectal cancer using its RAScan kits.
Transgenomic's chief commercial officer Chad Richards resigned effective May 10, the company said in a recent filing with the US Securities and Exchange Commission. Transgenomic said it has not named a replacement.
NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market Wednesday that its first-quarter revenues inched up 2 percent as an increase in sales from its laboratory services unit were offset by lower instrument sales.
The Trump Administration is reconsidering its plan to issue an executive order to require federally funded research to be freely available upon publication, Times Higher Education reports.
In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.
